Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms

Neftali Ortega Alarcon; Maddy Jaramillo; Heidi M. Mansour; Bo Sun

doi:10.3390/pharmaceutics14071448

Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms

Neftali Ortega Alarcon, Maddy Jaramillo, Heidi M. Mansour, Bo Sun

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

For decades, vaccines have played a significant role in protecting public and personal health against infectious diseases and proved their great potential in battling cancers as well. This review focused on the current progress of therapeutic subunit vaccines for cancer immunotherapy. Antigens and adjuvants are key components of vaccine formulations. We summarized several classes of tumor antigens and bioinformatic approaches of identification of tumor neoantigens. Pattern recognition receptor (PRR)-targeting adjuvants and their targeted delivery platforms have been extensively discussed. In addition, we emphasized the interplay between multiple adjuvants and their combined delivery for cancer immunotherapy.

Original language	English (US)
Article number	1448
Journal	Pharmaceutics
Volume	14
Issue number	7
DOIs	https://doi.org/10.3390/pharmaceutics14071448
State	Published - Jul 2022

Keywords

adjuvants
combination therapies
delivery systems
therapeutic vaccine
tumor antigens

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.3390/pharmaceutics14071448

Cite this

@article{e1f9d1980b1c4e13830b50434db0168c,

title = "Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms",

abstract = "For decades, vaccines have played a significant role in protecting public and personal health against infectious diseases and proved their great potential in battling cancers as well. This review focused on the current progress of therapeutic subunit vaccines for cancer immunotherapy. Antigens and adjuvants are key components of vaccine formulations. We summarized several classes of tumor antigens and bioinformatic approaches of identification of tumor neoantigens. Pattern recognition receptor (PRR)-targeting adjuvants and their targeted delivery platforms have been extensively discussed. In addition, we emphasized the interplay between multiple adjuvants and their combined delivery for cancer immunotherapy.",

keywords = "adjuvants, combination therapies, delivery systems, therapeutic vaccine, tumor antigens",

author = "Alarcon, {Neftali Ortega} and Maddy Jaramillo and Mansour, {Heidi M.} and Bo Sun",

note = "Funding Information: This work is supported by the Hispanic Serving Institute (HSI) Seed Grants and Skin Cancer Research Seed Grant at the University of Arizona. Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = jul,

doi = "10.3390/pharmaceutics14071448",

language = "English (US)",

volume = "14",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "7",

}

TY - JOUR

T1 - Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms

AU - Alarcon, Neftali Ortega

AU - Jaramillo, Maddy

AU - Mansour, Heidi M.

AU - Sun, Bo

N1 - Funding Information: This work is supported by the Hispanic Serving Institute (HSI) Seed Grants and Skin Cancer Research Seed Grant at the University of Arizona. Publisher Copyright: © 2022 by the authors.

PY - 2022/7

Y1 - 2022/7

N2 - For decades, vaccines have played a significant role in protecting public and personal health against infectious diseases and proved their great potential in battling cancers as well. This review focused on the current progress of therapeutic subunit vaccines for cancer immunotherapy. Antigens and adjuvants are key components of vaccine formulations. We summarized several classes of tumor antigens and bioinformatic approaches of identification of tumor neoantigens. Pattern recognition receptor (PRR)-targeting adjuvants and their targeted delivery platforms have been extensively discussed. In addition, we emphasized the interplay between multiple adjuvants and their combined delivery for cancer immunotherapy.

AB - For decades, vaccines have played a significant role in protecting public and personal health against infectious diseases and proved their great potential in battling cancers as well. This review focused on the current progress of therapeutic subunit vaccines for cancer immunotherapy. Antigens and adjuvants are key components of vaccine formulations. We summarized several classes of tumor antigens and bioinformatic approaches of identification of tumor neoantigens. Pattern recognition receptor (PRR)-targeting adjuvants and their targeted delivery platforms have been extensively discussed. In addition, we emphasized the interplay between multiple adjuvants and their combined delivery for cancer immunotherapy.

KW - adjuvants

KW - combination therapies

KW - delivery systems

KW - therapeutic vaccine

KW - tumor antigens

UR - http://www.scopus.com/inward/record.url?scp=85137301272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137301272&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics14071448

DO - 10.3390/pharmaceutics14071448

M3 - Review article

SN - 1999-4923

VL - 14

JO - Pharmaceutics

JF - Pharmaceutics

IS - 7

M1 - 1448

ER -

Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this